Dali Medical Devices announced today that it completed the first commercial implementation of the SAN-Light passive safety needle.
Tel Aviv, Israel-based Dali designed the SAN-Light single-use, sterile, hypodermic safety needle for compatibility with any Luer-lock syringe for subcutaneous or intramuscular drug administration.
SAN-Light makes up part of Dali’s SAN (safe auto needle) family of safety injectable drug delivery devices. All of the devices within the SAN family enable a more safe and easy-to-use injecting experience across a range of formulations, according to a news release.
Dali said the SAN-Light system includes an automatically-activated (passive) needle shield to reduce needlestick injuries, while the partially hidden needle alleviates needle anxiety.
SAN-Light was chosen for use with Advanz Pharma’s Mytolac/Myrelez, the first generic lanreotide drug product for treating acromegaly and gastroenteropancreatic neuroendocrine tumors. The product incorporates a prefilled syringe and a special version of the SAN-Light needle customized to fit the drug parameters and users’ needs.
“We are delighted to have worked with Advanz Pharma on this important, unique solution,” Dali CEO David Daily said in the release. “It’s a win-win collaboration that helps patients and enhances the commercialization of Advanz Pharma’s drug product by enabling a better experience and ease of administration.”